ClinicalTrials.gg
CompletedNCT06159790Updated Apr 9, 2026

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of GME751 and Keytruda-EU in Metastatic NSCLC, sponsored by Sandoz. Completed at 62 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis — 7 open to participants now, 15 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Novartis.

Enrollment
25th of 92
218 · median 91
Started
2024
the only one that year
Phase 3
15 of 101
none open now
Registered
94th of 101
by date

Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 25th largest by enrollment of the 92 interventional ones that give a count, is the only one that started in 2024, is one of 15 in phase 3, and was the 94th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status), without sensitizing EGFR or ALK mutations.

Read the detailed description

Eligible participants will be randomized in a 1:1 ratio to receive either GME751, or European Union (EU)-authorized pembrolizumab (Keytruda-EU) in combination with chemotherapy. The maximum study duration for a participant will be approximately 56 weeks including screening.

Treatment duration is 52 weeks (17 treatment cycles of study treatment GME751 or Keytruda-EU in combination with chemotherapy, each cycle with a duration of 3 weeks).

Participants will discontinue study participation in case of disease progression, unacceptable toxicity or other reasons.

Participants who are benefiting from treatment with pembrolizumab without signs of progression or unacceptable toxicity will be eligible for continued pembrolizumab treatment via most suitable option based on the respective country regulations.

03

Conditions studied

  • Metastatic NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Untreated NSCLC
  • Absence of tumor activating EGFR mutations and absence of ALK gene rearrangements
  • according to 1.1
  • Adequate organ function
  • (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Squamous cell or mixed histology in NSCLC
  • Known history of (grade ≥3) to pembrolizumab, chemotherapy or their
  • Active disease that has required chronic systemic treatment in the past 2 years.
  • Received ≤30 days before the first study treatment
  • Prior treatment with pembrolizumab or any other , or anti-PD-L1 or anti-PD-L2, or anti-CTLA-4 agent or any antibody targeting other immune-regulatory receptors or mechanisms for lung cancer.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    GME751 + pemetrexed + carboplatin or cisplatin

    Participants will receive GME751 + pemetrexed + carboplatin or cisplatin via intravenous (IV) infusion.

    Drug: GME751

  • Active comparator
    Keytruda-EU + pemetrexed + carboplatin or cisplatin

    Participants will receive Keytruda-EU + pemetrexed + carboplatin or cisplatin via intravenous (IV) infusion.

    Drug: Keytruda-EU

Interventions

  • DrugGME751

    Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)

  • DrugPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR)

    Best Overall Response (BOR) of either Complete Response (CR) or Partial Response (PR) up to 9 months according to RECIST 1.1 as assessed by Blinded Central Imaging

    Time frame: up to 9 months from date of randomization

07

Study locations

62 sites
  • Sandoz Investigational Site
    Fountain Valley, California 92708, United States
  • Sandoz Investigational Site
    Banja Luka, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Sarajevo, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Zenica, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Belo Horizonte, Brazil
  • Sandoz Investigational Site
    Fortaleza, Brazil
  • Sandoz Investigational Site
    Ipatinga, Brazil
  • Sandoz Investigational Site
    Porto Alegre, Brazil
  • Sandoz Investigational Site
    São José do Rio Preto, Brazil
  • Sandoz Investigational Site
    Batumi, Georgia
  • Sandoz Investigational Site
    Tbilisi, Georgia
  • Sandoz Investigational Site
    Rosenheim, Germany
  • Sandoz Investigational Site 2
    Ahmedabad, India
  • Sandoz Investigational Site
    Ahmedabad, India
  • Sandoz Investigational Site
    Bhubaneswar, India
  • Sandoz Investigational Site
    Hyderabad, India
  • Sandoz Investigational Site 2
    Mumbai, India
  • Sandoz Investigational Site
    Mumbai, India
  • Sandoz Investigational Site
    Nagpur, India
  • Sandoz Investigational Site
    Nashik, India
  • Sandoz Investigational Site
    New Delhi, India
  • Sandoz Investigational Site
    Varanasi, India
  • Sandoz Investigational Site
    Asahikawa, Japan
  • Sandoz Investigational Site
    Funabashi, Japan
  • Sandoz Investigational Site
    Hiroshima, Japan
  • Sandoz Investigational Site
    Kanazawa, Japan
  • Sandoz Investigational Site
    Niigata, Japan
  • Sandoz Investigational Site
    Okayama, Japan
  • Sandoz Investigational Site
    Sapporo, Japan
  • Sandoz Investigational Site
    Johor Bahru, Malaysia
  • Sandoz Investigational Site
    Kuala Lumpur, Malaysia
  • Sandoz Investigational Site
    Kuantan, Malaysia
  • Sandoz Investigational Site
    Kuching, Malaysia
  • Sandoz Investigational Site
    Malacca, Malaysia
  • Sandoz Investigational Site
    Petaling Jaya, Malaysia
  • Sandoz Investigational Site
    Putrajaya, Malaysia
  • Sandoz Investigational Site
    Bacolod, Philippines
  • Sandoz Investigational Site
    Cebu City, Philippines
  • Sandoz Investigational Site
    Makati, Philippines
  • Sandoz Investigational Site
    Cluj-Napoca, Romania
  • Sandoz Investigational Site
    Floreşti, Romania
  • Sandoz Investigational Site
    Kragujevac, Serbia
  • Sandoz Investigational Site
    A Coruña, Spain
  • Sandoz Investigational Site
    Córdoba, Spain
  • Sandoz Investigational Site
    Madrid, Spain
  • Sandoz Investigational Site
    Oviedo, Spain
  • Sandoz Investigational Site
    Douliu, Taiwan
  • Sandoz Investigational Site
    Kaohsiung City, Taiwan
  • Sandoz Investigational Site
    Taichung, Taiwan
  • Sandoz Investigational Site
    Taipei, Taiwan
  • Sandoz Investigational Site
    Bangkok, Thailand
  • Sandoz Investigational Site
    Khon Kaen, Thailand
  • Sandoz Investigational Site
    Adana, Turkey (Türkiye)
  • Sandoz Investigational Site
    Bursa, Turkey (Türkiye)
  • Sandoz Investigational Site
    Gaziantep, Turkey (Türkiye)
  • Sandoz Investigational Site
    Istanbul, Turkey (Türkiye)
  • Sandoz Investigational Site
    Malatya, Turkey (Türkiye)
  • Sandoz Investigational Site
    Sakarya, Turkey (Türkiye)
  • Sandoz Investigational Site
    Yüreğir, Turkey (Türkiye)
  • Sandoz Investigational Site
    Hanoi, Vietnam
  • Sandoz Investigational Site
    Hà Nội, Vietnam
  • Sandoz Investigational Site
    Ho Chi Minh City, Vietnam
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Mar 2026, 22 months.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 22 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Dec 7, 2023
StartActual
Apr 29, 2024
Primary completionActual
Mar 16, 2026
CompletionActual
Mar 16, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06159790
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Apr 29, 2024
Primary completion
Mar 16, 2026
Completion
Mar 16, 2026
Last update
Apr 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion